ArticlePharmacoEconomics - open2024

Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden.

Maria Polyzoi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.